Korean Journal of Biological Psychiatry (생물정신의학)

The Korean Society of Biological Psychiatry (대한생물정신의학회)
권호 표지

Association between the Brain-Derived Neurotropic Factor and Attention Deficit Hyperactivity Disorder

BDNF가 ADHD의 병인과 치료에 미치는 영향

  • Kang, Na Ri (Department of Psychiatry, Jeju Medical Center) ;
  • Song, Jae Min (Department of Psychiatry, Jeju Medical Center) ;
  • Kwack, Young-Sook (Department of Psychiatry, Jeju National University Hospital)
  • 강나리 (제주의료원 정신건강의학과) ;
  • 송재민 (제주의료원 정신건강의학과) ;
  • 곽영숙 (제주대학교병원 정신건강의학과)
  • Received : 2018.03.21
  • Accepted : 2018.05.08
  • Published : 2018.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

Attention deficit hyperactivity disorder (ADHD) is a common childhood psychiatric disorder. Recently, it has been suggested that brain-derived neurotropic factor (BDNF) may play a role in the pathogenesis of ADHD. Our aim of this review is to understand the physiological functions of BDNF and its potential relationship with ADHD and therapeutic approaches of ADHD. Searches were conducted in Pubmed and Research Information Service System (RISS). In this review, we summarized important literatures for the physiological functions of BDNF in neurodevelopment, change of serum BDNF level in ADHD, association of BDNF polymorphism and ADHD and potential association of treatment of ADHD with serum BDNF level. Further studies are required to more clearly understand the source and the role of BDNF in ADHD and to develop BDNF based-ADHD treatement.

Keywords

References

  1. Franke B, Faraone SV, Asherson P, Buitelaar J, Bau CH, Ramos- Quiroga JA, et al.; International Multicentre persistent ADHD CollaboraTion. The genetics of attention deficit/hyperactivity disorder in adults, a review. Mol Psychiatry 2012;17:960-987. https://doi.org/10.1038/mp.2011.138
  2. Patros CH, Alderson RM, Kasper LJ, Tarle SJ, Lea SE, Hudec KL. Choice-impulsivity in children and adolescents with attention-deficit/hyperactivity disorder (ADHD): a meta-analytic review. Clin Psychol Rev 2016;43:162-174. https://doi.org/10.1016/j.cpr.2015.11.001
  3. Gainetdinov RR, Caron MG. Genetics of childhood disorders: XXIV. ADHD, part 8: hyperdopaminergic mice as an animal model of ADHD. J Am Acad Child Adolesc Psychiatry 2001;40:380-382. https://doi.org/10.1097/00004583-200103000-00020
  4. Tsai SJ. Attention-deficit hyperactivity disorder and brain-derived neurotrophic factor: a speculative hypothesis. Med Hypotheses 2003;60:849-851. https://doi.org/10.1016/S0306-9877(03)00052-5
  5. Corominas-Roso M, Ramos-Quiroga JA, Ribases M, Sanchez-Mora C, Palomar G, Valero S, et al. Decreased serum levels of brain-derived neurotrophic factor in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 2013;16:1267-1275. https://doi.org/10.1017/S1461145712001629
  6. Traver S, Marien M, Martin E, Hirsch EC, Michel PP. The phenotypic differentiation of locus ceruleus noradrenergic neurons mediated by brain-derived neurotrophic factor is enhanced by corticotropin releasing factor through the activation of a cAMP-dependent signaling pathway. Mol Pharmacol 2006;70:30-40.
  7. Bergman O, Westberg L, Lichtenstein P, Eriksson E, Larsson H. Study on the possible association of brain-derived neurotrophic factor polymorphism with the developmental course of symptoms of attention deficit and hyperactivity. Int J Neuropsychopharmacol 2011;14:1367-1376. https://doi.org/10.1017/S1461145711000502
  8. Meredith GE, Callen S, Scheuer DA. Brain-derived neurotrophic factor expression is increased in the rat amygdala, piriform cortex and hypothalamus following repeated amphetamine administration. Brain Res 2002;949:218-227. https://doi.org/10.1016/S0006-8993(02)03160-8
  9. Chase T, Carrey N, Soo E, Wilkinson M. Methylphenidate regulates activity regulated cytoskeletal associated but not brain-derived neurotrophic factor gene expression in the developing rat striatum. Neuroscience 2007;144:969-984. https://doi.org/10.1016/j.neuroscience.2006.10.035
  10. Tsai SJ. Attention-deficit hyperactivity disorder may be associated with decreased central brain-derived neurotrophic factor activity: clinical and therapeutic implications. Med Hypotheses 2007;68:896-899. https://doi.org/10.1016/j.mehy.2006.06.025
  11. Maisonpierre PC, Belluscio L, Friedman B, Alderson RF, Wiegand SJ, Furth ME, et al. NT-3, BDNF, and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression. Neuron. 1990;5:501-509. https://doi.org/10.1016/0896-6273(90)90089-X
  12. Conner AC, Kissling C, Hodges E, Hunnerkopf R, Clement RM, Dudley E, et al. Neurotrophic factor-related gene polymorphisms and adult attention deficit hyperactivity disorder (ADHD) score in a high-risk male population. Am J Med Genet B Neuropsychiatr Genet 2008;147B:1476-1480. https://doi.org/10.1002/ajmg.b.30632
  13. Liu DY, Shen XM, Yuan FF, Guo OY, Zhong Y, Chen JG, et al. The physiology of BDNF and its relationship with ADHD. Mol Neurobiol 2015;52:1467-1476. https://doi.org/10.1007/s12035-014-8956-6
  14. Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991;350:230-232. https://doi.org/10.1038/350230a0
  15. Rapoport JL, Gogtay N. Brain neuroplasticity in healthy, hyperactive and psychotic children: insights from neuroimaging. Neuropsychopharmacology 2008;33:181-197. https://doi.org/10.1038/sj.npp.1301553
  16. Kernie SG, Liebl DJ, Parada LF. BDNF regulates eating behavior and locomotor activity in mice. EMBO J 2000;19:1290-1300. https://doi.org/10.1093/emboj/19.6.1290
  17. Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, Gemelli T, et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci U S A 2004;101:10827-10832. https://doi.org/10.1073/pnas.0402141101
  18. Martin-Iverson MT, Todd KG, Altar CA. Brain-derived neurotrophic factor and neurotrophin-3 activate striatal dopamine and serotonin metabolism and related behaviors: interactions with amphetamine. J Neurosci 1994;14:1262-1270. https://doi.org/10.1523/JNEUROSCI.14-03-01262.1994
  19. Leo D, Sukhanov I, Zoratto F, Illiano P, Caffino L, Sanna F, et al. Pronounced hyperactivity, cognitive dysfunctions, and BDNF dysregulation in dopamine transporter knock-out rats. J Neurosci 2018;38:1959-1972.
  20. Yeom CW, Park YJ, Choi SW, Bhang SY. Association of peripheral BDNF level with cognition, attention and behavior in preschool children. Child Adolesc Psychiatry Ment Health 2016;10:10. https://doi.org/10.1186/s13034-016-0097-4
  21. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1313-1323. https://doi.org/10.1016/j.biopsych.2004.11.024
  22. Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL, et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wildtype BDNF in neurosecretory cells and cortical neurons. J Neurosci 2004;24:4401-4411. https://doi.org/10.1523/JNEUROSCI.0348-04.2004
  23. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 2003;23:6690-6694. https://doi.org/10.1523/JNEUROSCI.23-17-06690.2003
  24. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003;112:257-269. https://doi.org/10.1016/S0092-8674(03)00035-7
  25. Ozturk O, Basay BK, Buber A, Basay O, Alacam H, Bacanli A, et al. Brain-derived neurotrophic factor gene Val66Met polymorphism is a risk factor for attention-deficit hyperactivity disorder in a Turkish sample. Psychiatry Investig 2016;13:518-525. https://doi.org/10.4306/pi.2016.13.5.518
  26. Lasky-Su J, Faraone SV, Lange C, Tsuang MT, Doyle AE, Smoller JW, et al. A study of how socioeconomic status moderates the relationship between SNPs encompassing BDNF and ADHD symptom counts in ADHD families. Behav Genet 2007;37:487-497. https://doi.org/10.1007/s10519-006-9136-x
  27. Schimmelmann BG, Friedel S, Dempfle A, Warnke A, Lesch KP, Walitza S, et al. No evidence for preferential transmission of common valine allele of the Val66Met polymorphism of the brain-derived neurotrophic factor gene (BDNF) in ADHD. J Neural Transm (Vienna) 2007;114:523-526. https://doi.org/10.1007/s00702-006-0616-1
  28. Lee J, Laurin N, Crosbie J, Ickowicz A, Pathare T, Malone M, et al. Association study of the brain-derived neurotropic factor (BDNF) gene in attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2007;144B:976-981. https://doi.org/10.1002/ajmg.b.30437
  29. Ortega-Rojas J, Arboleda-Bustos CE, Morales L, Benitez BA, Beltran D, Izquierdo A, et al. [Study of genetic variants in the BDNF, COMT, DAT1 and SERT genes in Colombian children with attention deficit disorder]. Rev Colomb Psiquiatr 2017;46:222-228. https://doi.org/10.1016/j.rcp.2016.08.006
  30. Park S, Kim BN, Kim JW, Jung YK, Lee J, Shin MS, et al. The role of the brain-derived neurotrophic factor genotype and parenting in early life in predicting externalizing and internalizing symptoms in children with attention-deficit hyperactivity disorder. Behav Brain Funct 2014;10:43. https://doi.org/10.1186/1744-9081-10-43
  31. Tzang RF, Hsu CD, Liou YJ, Hong CJ, Tsai SJ. Family-based association of the brain-derived neurotrophic factor gene in attentiondeficit hyperactivity disorder. Psychiatr Genet 2013;23:177-178. https://doi.org/10.1097/YPG.0b013e328360c8a9
  32. Ribases M, Hervas A, Ramos-Quiroga JA, Bosch R, Bielsa A, Gastaminza X, et al. Association study of 10 genes encoding neurotrophic factors and their receptors in adult and child attention-deficit/hyperactivity disorder. Biol Psychiatry 2008;63:935-945. https://doi.org/10.1016/j.biopsych.2007.11.004
  33. Sanchez-Mora C, Ribases M, Ramos-Quiroga JA, Casas M, Bosch R, Boreatti-Hummer A, et al. Meta-analysis of brain-derived neurotrophic factor p.Val66Met in adult ADHD in four European populations. Am J Med Genet B Neuropsychiatr Genet 2010;153B:512-523. https://doi.org/10.1002/ajmg.b.31008
  34. Lee YH, Song GG. BDNF 196 G/A and COMT Val158Met polymorphisms and susceptibility to ADHD: a meta-analysis. J Atten Disord 2015. pii: 1087054715570389. [Epub ahead of print]
  35. Cho SC, Kim HW, Kim BN, Kim JW, Shin MS, Chung S, et al. Gender-specific association of the brain-derived neurotrophic factor gene with attention-deficit/hyperactivity disorder. Psychiatry Investig 2010;7:285-290. https://doi.org/10.4306/pi.2010.7.4.285
  36. Li H, Liu L, Tang Y, Ji N, Yang L, Qian Q, et al. Sex-specific association of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and plasma BDNF with attention-deficit/hyperactivity disorder in a drug-naive Han Chinese sample. Psychiatry Res 2014;217:191-197. https://doi.org/10.1016/j.psychres.2014.03.011
  37. Cho SC, Kim JW, Kim HW, Kim BN, Shin MS, Cho DY, et al. Effect of ADRA2A and BDNF gene-gene interaction on the continuous performance test phenotype. Psychiatr Genet 2011;21:132-135. https://doi.org/10.1097/YPG.0b013e328341a389
  38. Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol 2011;14:347-353. https://doi.org/10.1017/S1461145710000738
  39. Pillai A, Kale A, Joshi S, Naphade N, Raju MS, Nasrallah H, et al. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol 2010;13:535-539. https://doi.org/10.1017/S1461145709991015
  40. Shim SH, Hwangbo Y, Kwon YJ, Jeong HY, Lee BH, Lee HJ, et al. Increased levels of plasma brain-derived neurotrophic factor (BDNF) in children with attention deficit-hyperactivity disorder (ADHD). Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1824-1828. https://doi.org/10.1016/j.pnpbp.2008.08.005
  41. Cubero-Millan I, Ruiz-Ramos MJ, Molina-Carballo A, Martinez-Serrano S, Fernandez-Lopez L, Machado-Casas I, et al. BDNF concentrations and daily fluctuations differ among ADHD children and respond differently to methylphenidate with no relationship with depressive symptomatology. Psychopharmacology (Berl) 2017;234:267-279. https://doi.org/10.1007/s00213-016-4460-1
  42. Saadat F, Kosha M, Amiry A, Torabi G. Brain-derived neurotrophic factor as a biomarker in children with attention deficit-hyperactivity disorder. JKIMSU 2015;4:10-17.
  43. Bilgic A, Toker A, Isik U, Kilinc I. Serum brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 levels in children with attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 2017;26:355-363. https://doi.org/10.1007/s00787-016-0898-2
  44. Simsek S, Gencoglan S, Yuksel T, Kaplan I, Aktas H, Alaca R. Evaluation of the relationship between brain-derived neurotropic factor levels and the stroop interference effect in children with attentiondeficit hyperactivity disorder. Noro Psikiyatr Ars 2016;53:348-352. https://doi.org/10.5152/npa.2016.10234
  45. Scassellati C, Zanardini R, Tiberti A, Pezzani M, Valenti V, Effedri P, et al. Serum brain-derived neurotrophic factor (BDNF) levels in attention deficit-hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry 2014;23:173-177. https://doi.org/10.1007/s00787-013-0447-1
  46. Sargin E, Pekcanlar Akay A, Resmi H, Alsen Cengizhan S, Ozek H, Ellidokuz H, et al. Evaluation of serum brain-derived neurotrophic factor levels in children with attention deficit hyperactivity disorder: preliminary data. Noropsikiatri Arsivi 2012;49:96-101. https://doi.org/10.4274/npa.y5958
  47. Zhang J, Luo W, Li Q, Xu R, Wang Q, Huang Q. Peripheral brain-derived neurotrophic factor in attention-deficit/hyperactivity disorder: a comprehensive systematic review and meta-analysis. J Affect Disord 2018;227:298-304. https://doi.org/10.1016/j.jad.2017.11.012
  48. Rosenfeld RD, Zeni L, Haniu M, Talvenheimo J, Radka SF, Bennett L, et al. Purification and identification of brain-derived neurotrophic factor from human serum. Protein Expr Purif 1995;6:465-471. https://doi.org/10.1006/prep.1995.1062
  49. Trajkovska V, Marcussen AB, Vinberg M, Hartvig P, Aznar S, Knudsen GM. Measurements of brain-derived neurotrophic factor: methodological aspects and demographical data. Brain Res Bull 2007;73:143-149. https://doi.org/10.1016/j.brainresbull.2007.03.009
  50. Horger BA, Iyasere CA, Berhow MT, Messer CJ, Nestler EJ, Taylor JR. Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. J Neurosci 1999;19:4110-4122. https://doi.org/10.1523/JNEUROSCI.19-10-04110.1999
  51. Simchon-Tenenbaum Y, Weizman A, Rehavi M. Alterations in brain neurotrophic and glial factors following early age chronic methylphenidate and cocaine administration. Behav Brain Res 2015;282:125-132. https://doi.org/10.1016/j.bbr.2014.12.058
  52. Amiri A, Torabi Parizi G, Kousha M, Saadat F, Modabbernia MJ, Najafi K, et al. Changes in plasma brain-derived neurotrophic factor (BDNF) levels induced by methylphenidate in children with attention deficit-hyperactivity disorder (ADHD). Prog Neuropsychopharmacol Biol Psychiatry 2013;47:20-24. https://doi.org/10.1016/j.pnpbp.2013.07.018
  53. Akay AP, Resmi H, Guney SA, Erkuran HO, Ozyurt G, Sargin E, et al. Serum brain-derived neurotrophic factor levels in treatment-naive boys with attention-deficit/hyperactivity disorder treated with methylphenidate: an 8-week, observational pretest-posttest study. Eur Child Adolesc Psychiatry 2018;27:127-135. https://doi.org/10.1007/s00787-017-1022-y
  54. Narita M, Aoki K, Takagi M, Yajima Y, Suzuki T. Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuroscience 2003;119:767-775. https://doi.org/10.1016/S0306-4522(03)00099-X
  55. Ramos-Quiroga JA, Corominas-Roso M, Palomar G, Gomez-Barros N, Ribases M, Sanchez-Mora C, et al. Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine. Psychopharmacology (Berl) 2014;231:1389-1395. https://doi.org/10.1007/s00213-013-3343-y
  56. Del'Guidice T, Lemasson M, Etievant A, Manta S, Magno LA, Escoffier G, et al. Dissociations between cognitive and motor effects of psychostimulants and atomoxetine in hyperactive DAT-KO mice. Psychopharmacology (Berl) 2014;231:109-122. https://doi.org/10.1007/s00213-013-3212-8
  57. Kim BN, Cummins TDR, Kim JW, Bellgrove MA, Hong SB, Song SH, et al. Val/Val genotype of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with a better response to OROS-MPH in Korean ADHD children. Int J Neuropsychopharmacol 2011;14:1399-1410. https://doi.org/10.1017/S146114571100099X
  58. Park JH. Atomoxetine alleviates the symptoms of attention deficit hyperactivity disorder (ADHD) through enhancing of dopamine synthesis and neuronal activity in rats. Seoul: Kyung Hee University; 2010.
  59. Gunnar MR, Wenner JA, Thomas KM, Glatt CE, McKenna MC, Clark AG. The brain-derived neurotrophic factor Val66Met polymorphism moderates early deprivation effects on attention problems. Dev Psychopathol 2012;24:1215-1223. https://doi.org/10.1017/S095457941200065X
  60. Kent L, Green E, Hawi Z, Kirley A, Dudbridge F, Lowe N, et al. Association of the paternally transmitted copy of common Valine allele of the Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene with susceptibility to ADHD. Mol Psychiatry 2005;10:939-943. https://doi.org/10.1038/sj.mp.4001696